More Articles Back to Article
France approves national reimbursement deal for CF drug Orkambi
The French authorities have approved a national reimbursement deal for Vertex Pharmaceuticals' drug Orkambi, or lumacaftor/ivacaftor, to treat patients with cystic fibrosis who have two copies of the F508del mutation in their CTFR gene. France has among the largest population of patients with CF after the UK and the US. PMLive (UK) (11/21)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!